Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):706–712. doi: 10.1038/bjc.1993.130

Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.

S M Allan 1, C Dean 1, I Fernando 1, S Eccles 1, J Styles 1, V R McCready 1, M Baum 1, N Sacks 1
PMCID: PMC1968376  PMID: 8097104

Abstract

Lymph node status is still the single most important prognostic factor in breast cancer. Axillary surgery remains the only reliable means of providing this information. This pilot study evaluates using a highly specific radiolabelled monoclonal antibody to provide equivalent information by a non-invasive technique. After optimisation of labelling conditions, our first antibody, ICR12 (against the gene product of c-erbB-2) was evaluated in a mouse model system. Twenty-four hours post i.v. injection the mice were killed and their organs, blood and tumours harvested for counting. Tumour localisation was four times greater than that into normal tissues, reaching 20% injected dose per gram of tumour. Eight patients have had this Tc99m-ICR12. Patient selection was by immunocytochemical staining of fine needle aspirates from the patient's own breast cancer. After intravenous administration of the immunoconjugate, tomographic images were obtained at 24 h. These results were compared to the subsequent histopathological examinations. Three patients acted as normal controls, one patient was negative due to inappropriate sampling, and two patients had strong membrane staining and provided excellent tumour localisation to both breast primary and regional node metastases. A further two patients only had moderate antigen expression on staining and did not localise well. The good performance of this radiolabelled antibody with patients that strongly stain for the antigen encourages the development of this system as both a method of staging breast cancer and a potential means of immunotherapy in this subgroup of patients.

Full text

PDF
706

Images in this article

707Figure 1
on p.707
709Figure 3
on p.709
710Figure 5
on p.710
711Figure 6
on p.711
711Figure 7
on p.711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Athanassiou A., Pectasides D., Pateniotis K., Tzimis L., Natsis P., Lafi A., Arapantoni P., Koutsiouba P., Taylor-Papadimitriou J., Epenetos A. Immunoscintigraphy with 131I-labelled HMFG2 and HMFG1 F(ab')2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int J Cancer Suppl. 1988;3:89–95. doi: 10.1002/ijc.2910410818. [DOI] [PubMed] [Google Scholar]
  2. Bakir M. A., Eccles S., Babich J. W., Aftab N., Styles J., Dean C. J., Lambrecht R. M., Ott R. J., Eccles S. A., Styles J. M. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med. 1992 Dec;33(12):2154–2160. [PubMed] [Google Scholar]
  3. Cockcroft S., Taylor J. A., Judah J. D. Subcellular localisation of inositol lipid kinases in rat liver. Biochim Biophys Acta. 1985 May 30;845(2):163–170. doi: 10.1016/0167-4889(85)90173-9. [DOI] [PubMed] [Google Scholar]
  4. Gusterson B. A., Gelber R. D., Goldhirsch A., Price K. N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul;10(7):1049–1056. doi: 10.1200/JCO.1992.10.7.1049. [DOI] [PubMed] [Google Scholar]
  5. Gusterson B. A., Machin L. G., Gullick W. J., Gibbs N. M., Powles T. J., Price P., McKinna A., Harrison S. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer. 1988 Dec 15;42(6):842–845. doi: 10.1002/ijc.2910420608. [DOI] [PubMed] [Google Scholar]
  6. Mather S. J., Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med. 1990 May;31(5):692–697. [PubMed] [Google Scholar]
  7. Perren T. J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer. 1991 Mar;63(3):328–332. doi: 10.1038/bjc.1991.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Schlom J. Innovations in monoclonal antibody tumor targeting. Diagnostic and therapeutic implications. JAMA. 1989 Feb 3;261(5):744–746. [PubMed] [Google Scholar]
  9. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  10. Styles J. M., Harrison S., Gusterson B. A., Dean C. J. Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. Int J Cancer. 1990 Feb 15;45(2):320–324. doi: 10.1002/ijc.2910450219. [DOI] [PubMed] [Google Scholar]
  11. Thompson C. H., Lichtenstein M., Stacker S. A., Leyden M. J., Salehi N., Andrews J. T., McKenzie I. F. Immunoscintigraphy for detection of lymph node metastases from breast cancer. Lancet. 1984 Dec 1;2(8414):1245–1247. doi: 10.1016/s0140-6736(84)92798-3. [DOI] [PubMed] [Google Scholar]
  12. Tjandra J. J., Russell I. S., Collins J. P., Andrews J. T., Lichtenstein M., Binns D., McKenzie I. F. Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer. Cancer Res. 1989 Mar 15;49(6):1600–1608. [PubMed] [Google Scholar]
  13. Tjandra J. J., Sacks N. P., Thompson C. H., Leyden M. J., Stacker S. A., Lichtenstein M., Russell I. S., Collins J. P., Andrews J. T., Pietersz G. A. The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study. Br J Cancer. 1989 Feb;59(2):296–302. doi: 10.1038/bjc.1989.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vaickus L., Foon K. A. Overview of monoclonal antibodies in the diagnosis and therapy of cancer. Cancer Invest. 1991;9(2):195–209. doi: 10.3109/07357909109044230. [DOI] [PubMed] [Google Scholar]
  15. Wright C., Nicholson S., Angus B., Sainsbury J. R., Farndon J., Cairns J., Harris A. L., Horne C. H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992 Jan;65(1):118–121. doi: 10.1038/bjc.1992.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Yiu C. Y., Baker L. A., Boulos P. B. Anti-epithelial membrane antigen monoclonal antibodies and radioimmunolocalization of colorectal cancer. Br J Surg. 1991 Oct;78(10):1212–1215. doi: 10.1002/bjs.1800781020. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES